Clinical Trial Update: A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ibrutinib in combination with R-CHOP in newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)
• ibrutinib (PCI-32765) (ibrutinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2019-03-19